F-star Announces Issuance of US Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 & LAG-3
F-star Therapeutics, Inc. recently announced the USPTO has granted a patent protecting the composition of matter of FS118, F-star’s tetravalent bispecific antibody which blocks PD-L1 and LAG-3 receptors. US Patent No. 11,214,620 is titled Binding Molecules Binding PD-L1 and LAG-3 and is expected to provide F-star with exclusivity for FS118 out to at least August 2038.
Neil Brewis, Chief Scientific Officer of F-star Therapeutics, Inc., said “This newly issued US patent expands our already broad and robust patent portfolio and further supports the commercial potential of FS118. The growth of our IP portfolio surrounding our tetravalent bispecific antibody discovery platform, as well as our proprietary clinical-stage assets is a core strategic focus for F-star that we believe is creating significant value for our shareholders.”
F-star currently has over 500 granted and pending patents covering its platform technology and product pipeline.
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. F-star is pioneering the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in cancer therapy. The Company has four second-generation immuno-oncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate. F-star has over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS. For more information visit our website.
Total Page Views: 723
